Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to phase 2 study results presented by Adam Olszewski, MD.
As oncology contemplates the potential impact of a second Donald Trump term on cancer care and research, The Cancer Letter has compiled a list of…
Current up-front therapeutic approaches for classic Hodgkin lymphoma (cHL) in children and young adults aim to reduce treatment intensity to minimize long-term treatment-related morbidity. This…
Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematology and Hematological Oncology (VJHemOnc). This exclusive session features experts Vaishali Sanchorawala…
Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin…
In this issue of Blood, Ito et al1 present a compelling cost-effectiveness analysis of iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH
Key PointsNaratuximab emtansine has strong antitumor activity even in models with poor outcome genetic lesions or R-CHOP resistance.PI3Kδ activation, IL-6
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…
Data from a phase 1b/2 trial show improvements in overall survival with amezalpat plus atezolizumab/bevacizumab among patients with metastatic HCC.
